Table 2.
Prognostic significance of TS, DPD and TP cytoplasmic expression level in different CRC stage and treatment groups
| Stage and treatment | No. of cases (low, high) | HR | 95% CI | P |
|---|---|---|---|---|
| Stage II (surgery alone) | ||||
| TS low versus TS high | 302, 216 | 1.69 | 1.09–2.63 | 0.019 |
| DPD low versus DPD high | 121, 323 | 1.92 | 1.23–2.94 | 0.003 |
| TP low versus TP high | 199, 318 | 1.16 | 0.78–1.75 | 0.449 |
| Stage III (surgery alone) | ||||
| TS low versus TS high | 147, 78 | 1.39 | 0.92–2.13 | 0.124 |
| DPD low versus DPD high | 97, 124 | 1.49 | 1.02–2.17 | 0.038 |
| TP low versus TP high | 87, 133 | 1.05 | 0.71–1.54 | 0.812 |
| Stage III (5-FU chemotherapy) | ||||
| TS low versus TS high | 83, 42 | 0.81 | 0.49–1.33 | 0.415 |
| DPD low versus DPD high | 58, 65 | 0.70 | 0.42–1.15 | 0.160 |
| TP low versus TP high | 44, 86 | 0.66 | 0.39–1.12 | 0.129 |
TS, thymidylate synthase; DPD, dihydropyrimidine dehydrogenase; TP, thymidine phosphorylase; CRC, colorectal cancer; HR, hazard ratio; CI, confidence interval; 5-FU, 5-fluorouracil.